Baili Tianheng announced that t-Bren independently developed by the company was used in phase III clinical trials of unresectable locally advanced or metastatic HER2 positive breast cancer where treatment with trastuzumab and paclitaxel failed. According to the independent data monitoring committee, the analysis reached the main end point of progression-free survival. This is the first phase III clinical study where this ADC reached its primary endpoint.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.